Myelodysplastic syndromes: molecular pathogenesis and genomic changes

被引:0
|
作者
Florian Nolte
Wolf-K. Hofmann
机构
[1] University Hospital Benjamin Franklin,Department of Hematology and Oncology
来源
Annals of Hematology | 2008年 / 87卷
关键词
Angiogenesis; Bone marrow stroma cells; Cell cycle control; Deletion 20q; DNA-methylation; Gene expression profiling; JAK2-mutations; Mitochondrial DNA; Moleculargenetic changes; Myelodysplastic syndrome; SNP-analysis; 5q-syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis presenting with peripheral cytopenias in combination with a hyperplastic bone marrow and an increased risk of evolution to acute myeloid leukemia. The classification systems such as the WHO classification mainly rely on morphological criteria and are supplemented by the International Prognostic Scoring System which takes cytogenetical changes into consideration when determining the prognosis of MDS but wide intra-subtype variations do exist. The pathomechanisms causing primary MDS require further work. Development and progression of MDS is suggested to be a multistep alteration to hematopoietic stem cells. Different molecular alterations have been described, affecting genes involved in cell-cycle control, mitotic checkpoints, and growth factor receptors. Secondary signal proteins and transcription factors, which gives the cell a growth advantage over its normal counterpart, may be affected as well. The accumulation of such defects may finally cause the leukemic transformation of MDS.
引用
收藏
页码:777 / 795
页数:18
相关论文
共 50 条
  • [31] The Genomic Landscape of Pediatric Myelodysplastic Syndromes
    Schwartz, Jason
    Ma, Jing
    Walsh, Michael
    Lamprecht, Tamara
    Wang, Shuguo
    Wu, Gang
    Easton, John
    Ribeiro, Raul
    Klco, Jeffery
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S7 - S7
  • [32] The genomic landscape of pediatric myelodysplastic syndromes
    Jason R. Schwartz
    Jing Ma
    Tamara Lamprecht
    Michael Walsh
    Shuoguo Wang
    Victoria Bryant
    Guangchun Song
    Gang Wu
    John Easton
    Chimene Kesserwan
    Kim E. Nichols
    Charles G. Mullighan
    Raul C. Ribeiro
    Jeffery M. Klco
    Nature Communications, 8
  • [33] Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies
    Harada, Hironori
    Harada, Yuka
    CANCER SCIENCE, 2015, 106 (04) : 329 - 336
  • [34] Distinct Pattern Of Genomic Changes Associated With Smoking In Patients With Myelodysplastic Syndromes (MDS)
    Seastone, David J.
    Mukherjee, Sudipto
    Otrock, Zaher K.
    Elson, Paul
    Keng, Michael K.
    Przychodzen, Bartlomiej
    Makishima, Hideki
    Dienes, Brittney
    Hobson, Sean
    Dodd, Kristin
    Cinalli, Tracy
    Tiu, Ramon V.
    Saunthararajah, Yogen
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2013, 122 (21)
  • [35] Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)
    Valent, P
    Wimazal, F
    Schwarzinger, I
    Sperr, WR
    Geissler, K
    WIENER KLINISCHE WOCHENSCHRIFT, 2003, 115 (13-14) : 515 - 536
  • [36] Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Warlick, Erica D.
    Miller, Jeffrey S.
    LEUKEMIA & LYMPHOMA, 2011, 52 (11) : 2045 - 2049
  • [37] Pathogenesis, biology, and management of myelodysplastic syndromes in children
    Haas, OA
    Gadner, H
    SEMINARS IN HEMATOLOGY, 1996, 33 (03) : 225 - 235
  • [38] miRNAs, Immune Signaling, and Myelodysplastic Syndromes Pathogenesis
    Karsan, Aly
    BLOOD, 2014, 124 (21)
  • [39] Myelodysplastic syndromes: From pathogenesis and prognosis to treatment
    Fenaux, P
    SEMINARS IN HEMATOLOGY, 2004, 41 (02) : 6 - 12
  • [40] Pathogenesis of immunological abnormalities in myelodysplastic syndromes.
    Okamoto, T
    Okada, M
    Takemoto, Y
    Kanamaru, A
    Kakishita, E
    BLOOD, 1997, 90 (10) : 2316 - 2316